Article

I-MED Pharma USA gains distribution rights for ESW Vision’s dry eye devices

I-MED Pharma Inc., a Canadian-based firm, announced this week the expansion of its strategic partnership with ESW Vision in France to be their exclusive distributor in the United States.

Montreal-based I-MED Pharma Inc. announced this week the expansion of its strategic partnership with ESW Vision in France to be their exclusive distributor in the United States.

Through I-MED Pharma USA, two dry eye devices will be available directly to all eye care professionals across the country.

E>Eye, is the first and only CE certified medical device in the world using patented IRPL technology developed specifically for the treatment of dry eye disease caused by meibomian gland dysfunction (MGD), the leading cause of evaporative dry eye.

Philipp Binder

Philipp Binder

According to the company, this form of polychromatic pulsed light produces calibrated and homogeneously sequenced “cold light” pulses which safely stimulate the meibomian glands to resume secretions, restoring the lacrymal film and improving symptoms associated with ocular dryness.

Tearcheck is a dry eye diagnostic and analyzer tool that performs nine exams in under ten minutes. The innovative technology and unique usability of this diagnostic device creates a new standard for dry eye analysis.

According to Philipp Binder, president and COO of I-MED Pharma, the company is proud to be building on the worldwide success of these dry eye devices.

“With thousands of units installed worldwide, this technology has become globally regarded as the gold standard,” he said in a statement. These devices have been quickly recognized as the number one technology in Canada by eye care professionals, and we are excited to bring this innovation to the US market. Our strategic collaboration with ESW Vision over the last three years has pushed us forward in our mission to bring complete relief to dry eye and ocular surface disease patients worldwide.”

I-MED Pharma USA is a subsidiary of I-MED Pharma Inc., a privately held Canadian company, headquartered in Montreal, Quebec.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
(Image credit: Ophthalmology Times) Oluwatosin U. Smith talks Glaukomtecken
© 2025 MJH Life Sciences

All rights reserved.